New Advances in Treating Adult Atopic Dermatitis

Recent updates to the guidelines for managing atopic dermatitis in adults highlight four new, evidence-based treatment options, published in the Journal of the American Academy of Dermatology. These recommendations aim to improve patient outcomes with targeted therapies. Dawn M.R. Davis from the Mayo Clinic and colleagues reviewed current evidence to strengthen treatment protocols, emphasizing the use of both topical and systemic options for different severity levels of the condition.

For moderate-to-severe atopic dermatitis, the corticosteroid-free tapinarof cream is now recommended, providing an alternative to traditional corticosteroids with fewer side effects. For milder cases, roflumilast 0.15% cream offers a new topical option. In cases of moderate-to-severe disease, biologic agents lebrikizumab and nemolizumab, combined with topical therapy, are advocated due to their high efficacy.

The authors stressed the need for more long-term safety and real-world data to better understand these therapies' effectiveness and patient-reported outcomes. They also highlighted the importance of comparative studies to determine the optimal role of these new treatments within the broader range of existing therapies.

These advances represent significant progress in personalized care for adult atopic dermatitis, offering hope for better symptom control and improved quality of life for patients.

Source: https://medicalxpress.com/news/2025-07-treatments-atopic-dermatitis-adults.html